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Abstract 
The remarkable stability of microRNAs in biofluids underlies their potential as biomarkers, but their 
small size presents challenges for detection by RT-qPCR. The heterogeneity of microRNAs, with each 
one comprising a series of variants or ‘isomiRs’, adds additional complexity.  Presented here are the 
key considerations for use of RT-qPCR to measure microRNAs and their isomiRs, with a focus on 
plasma. Modified nucleotides can be incorporated into primer sequences to enhance affinity and 
provide increased specificity and sensitivity for RT-qPCR assays. Approaches based upon polyA tailing 
and use of a common oligo(dT)-based reverse transcription oligonucleotide will detect most isomiRs. 
Conversely, stem-loop RT oligonucleotides and sequence specific probes can enable detection of 
specific isomiRs of interest. Next generation sequencing of all the products of a microRNA RT-PCR 
reaction is a promising new approach for both microRNA quantification and characterization. 
Keywords: 
microRNA, miRNA,  isomiR, RT-qPCR, biomarker, NGS 
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Introduction 
MicroRNAs are small RNAs in the range of 18-22 ribonucleotides in length [1]. They are stable in 
biofluids due to protection from exonucleolytic degradation by incorporation in protein complexes 
or containment within vesicles. A plethora of published studies describe the diagnostic potential of 
circulating microRNAs for both malignant and non-malignant diseases [2][3][4][5][6][7][8][9]. A 
range of parameters is critical to the design of a successful PCR assay, firstly careful design of 
primers to ensure specificity, harmonise melting temperatures and avoid formation of dimers. 
However, primer design options for amplification of microRNAs are severely limited because the 
primer sequence is dictated by their small size. Another feature of microRNAs is that they form 
families with similar sequences, making it difficult to design PCR assays with sufficient specificity to 
discriminate between family members. Furthermore, individual microRNAs exist as a series of 
isoforms or ‘isomiRs’ which vary in length and/or sequence [10] [11] and have exciting diagnostic 
potential [12][13]. Expression level and proportion of microRNA isomiRs alters in response to 
bacterial infection [14]. The design of a PCR assay will determine whether it detects just some or all 
of the isomiRs of the target microRNA.   
To develop an optimal RT-qPCR assay to measure microRNAs for molecular diagnosis it is necessary 
to consider the whole workflow (Figure 1). Regardless of the choice of nucleic acid extraction 
protocol, it is critical that the samples are processed in a consistent fashion, with automation where 
possible [15]. Stringent RNA quality control should be performed by both spectrophotometric 
methods to determine purity and fluorimetry with RNA-binding dyes to determine concentration 
[16][17]. It is imperative that such steps are employed to reduce technical variation and therefore 
minimise the need for downstream normalisation procedures which complicate interpretation of the 
data. Considerations for optimising each step in the RT-qPCR workflow are addressed in the 
following sections. 
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RNA extraction 
Many options are available for microRNA extraction from tissue and biofluids (reviewed by 
Moldovan et al [16]). One of the most common methods of extraction, particularly from tissues, 
involves phenol and guanidinium thiocyanate (e.g. Qiazol®/Trizol®). Bead-based capture techniques 
amenable to automation (e.g. Agencourt  RNAdvance Blood Kit for MicroRNA, Beckman Coulter) are 
beginning to emerge. However, column-based (silica or proprietary resin) methodologies are the 
most commonly used, in particular for biofluids. The Exiqon miRCURY™ RNA Isolation Biofluids kit 
has been shown to outperform isolation kits available from other vendors in the isolation of 
microRNAs from plasma[18]; especially given its ease of use and short processing time it should be 
considered when choosing a microRNA isolation kit for plasma. The kit is also suggested for serum 
and urine, although to date there are no comparative studies for these biofluids. Both the phenol 
guanidinium thiocyanate method and column-based approaches can be carried out with or without 
short RNA enrichment, the impact of which is reviewed by Redshaw et al [19].  
The effectiveness of microRNA isolation technologies can vary depending upon the properties of the 
specific samples and the RT-qPCR assay employed [15][19][20] and it is therefore advisable to assess 
various combinations when optimising a new assay. It is particularly important to test different 
volumes of input material; we and others have observed that the yield of microRNA from plasma (as 
judged by RT-qPCR) does not increase linearly as expected with increasing volume [21], presumably 
due to decreased isolation efficiency or presence of inhibitors [18]. A lesser effect was reported with 
increasing volumes of murine serum [22] and the phenomenon is not observed with other biofluids, 
such as cerebrospinal fluid, perhaps because lower protein content reduces column clogging [18]. 
However, it should be noted that extraction from small amounts of starting material can result in the 
selective loss of microRNAs with low GC content or high secondary structure [23]. 
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Direct quantification of microRNAs from cells or biofluids presents an attractive option to both 
simplify and therefore speed up the RT-qPCR workflow and remove bias introduced by preferential 
purification of certain sequences [11]. It is possible to detect microRNAs in cells lysed with 
commercial (eg TaqMan MicroRNA Cells-to-CT Kit, Thermo Fisher Scientific) or in-house detergent 
solutions [7][24][14]. We have successfully amplified miR-22 and miR-34a directly from 100 
endothelial colony forming cells (ECFCs [25]) lysed with a buffer containing Nonidet P40 and Triton 
X100 [24] (Figure 2). Asaga and colleagues in 2011 were the first to report a direct RT-qPCR protocol 
(which they termed RT-qPCR-DS) to detect circulating microRNAs in sera from cancer patients [5].  
Commercially, SomaGenics( http://www.somagenics.com/ ) have developed a miR-Direct™ system 
which uses a capture probe followed by a solution phase hybridisation to capture the probes which 
they claim improves the capture of low abundance microRNAs. This hybridisation step also facilitates 
washing to remove any potential PCR inhibitors. Quantification of microRNAs occurs with 
SomaGenics' miR-ID® technology [26]. Circularization of the target microRNAs during this step 
prevents re-hybridization to the immobilized capture probe and thereby is claimed to improve the 
sensitivity and reproducibility. The entire miR-Direct™ procedure is performed in a single tube and is 
reported to be amenable to automation. This technology has been used to measure expression of 
circulating microRNAs in plasma [27]. 
Reverse transcription (RT)  
The two most widely used strategies for reverse transcription (RT) of microRNAs involve either 
addition of a polyA tail and priming with an anchored oligo(dT) RT oligonucleotide or use of a stem-
loop microRNA-specific RT oligonucleotide (Figure 3)[16]. If assaying for multiple specific microRNAs, 
some RT reactions may be sub-optimal due to variations in the sequence-dependent hybridisation of 
each primer. A pulsed RT methodology (e.g. 40 cycles of 16°C for 2 min, 42°C for 1 min and 50°C for 
1 s, followed by a final reverse transcriptase inactivation step at 85°C for 5 min) may provide 
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conditions for all targets to be efficiently reverse transcribed [28]. An advantage of the polyA-
oligo(dT) methodology is the potential to return to the cDNA at any point and assay for another 
microRNA; in contrast, the direct methodology is limited to those microRNAs with specific primers 
included in the RT. 
The simultaneous amplification of all isomiRs from oligo(dT)-primed cDNA provides greater 
theoretical sensitivity for this approach, but this is offset by the potential for greater specificity and 
therefore reduced noise of microRNA-specific  reverse transcription. The use of stem loop 
oligonucleotides which overlap the 3′ end of the target microRNA to prime reverse transcription 
adds an additional level of specificity prior to amplification [29]. This step is employed by the widely 
used TaqMan™ miRNA Assays (Thermo Fisher Scientific) in which a hydrolysis probe is subsequently 
used to quantify the product amplified by a microRNA-specific forward and common reverse primer. 
While very effective at discriminating between closely related microRNAs, this approach is not 
completely specific for a single 3′ isomiR of the target microRNA. For example, although a TaqMan 
assay designed to detect mature miR-127-3p did not detect a 3′ isomiR which was two nucleotides 
shorter than the mature sequence, an assay designed to detect the isomiR amplified both the isomiR 
and mature sequences with similar efficiency [30]. Comparable findings have been reported for 
TaqMan assays designed to detect isomiRs of miR-877-5p or miR-33b-5p [31]. The ligation of stem-
loop adaptors to both the 5′ and 3′ ends of the target microRNA to create a ‘dumbbell-like’ structure 
which can then be quantified by TaqMan RT-qPCR enables the selective quantification of specific 
isomiRs[32]. Another methodology with a specific RT step involves the use of microRNA-specific 
‘conformation-restricted’ RT primers (MiRXES) [33][34]. Use of microRNA-specific forward and 
nested reverse primers increases the specificity of MiRXES assays and because there are no universal 
primers generation of non-specific cDNA is minimised. Unlike TaqMan assays, amplification is 
detected using SYBR Green allowing for rapid amplification at a lower cost.   
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In an alternative approach developed by Castoldi and colleagues [35] termed ‘miQPCR’, T4 ligase is 
used to ligate an adaptor to the microRNA 3' end. Ligation of the 26nt oligonucleotide adaptor 
(miLINKER) provides a template for RT with a complementary primer. An important feature of this 
technique is that the linker does not contain the full sequence of the universal qPCR primer, which is 
introduced into the amplicon during reverse transcription with the specific primer. This is proposed 
to increase the specificity of the assay and also results in the ability to change the universal PCR 
primer without having to change the miLINKER sequence. 
Choice of PCR primers 
Formation of primer dimers and off target amplicons can interfere with the amplification of the 
target amplicon causing signal dampening, false-negatives and even false-positives. Careful design of 
primer sequences to enhance specificity and minimise primer:primer complementarity and 
therefore formation of primer dimers is critical for all PCR reactions and is thoroughly reviewed in a 
recent book dedicated to this topic [36]. Many computer algorithms are available to help the end 
user, for example primer3 [37][38][39]. Unfortunately the short length of microRNAs severely limits 
the choice of primer sequence. This restriction can be partially circumvented by addition of a tail at 
the 5′ end of the primer, an approach incorporated in publicly available ‘miRprimer’ software for 
design of primers for ‘miR-specific RT-qPCR’ [40]. The specificity of miRprimer assays is increased by 
designing reverse primers with 3-8 nucleotides complementary to the microRNA.  Candidate primers 
are adjusted to a Tm of 59°C by trimming or addition of nucleotides and optimum primer pairs 
selected to minimise formation of secondary structures and primer dimers.   
Incorporation of modified nucleotides, most commonly ‘Locked Nucleic Acid’ (LNA) (Exiqon), can 
significantly enhance the affinity of an oligonucleotide for its complementary target sequence. A 
mixed LNA/DNA oligonucleotide can therefore be designed to have a similar affinity towards 
different microRNA sequences with varying GC-content [41]. An increase in duplex melting 
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temperature (Tm) of 2-8 °C for each incorporated LNA nucleotide means that LNA oligonucleotides 
can be made shorter than traditional DNA oligonucleotides and still retain a high Tm.  
 
In many cases it is possible to discriminate between related microRNAs with similar sequences using 
conventional oligonucleotide primers for amplification. The optimum annealing temperature that 
distinguishes between hybridisation of a primer to its perfectly matched intended target and 
hybridisation with mismatch(es) to a similar off-target sequence can be determined experimentally. 
Using this approach it was possible to discriminate effectively between miR-135a and miR-13b, 
which differ by only a single base [42]. However, incorporation of modified nucleotides into primers 
can reduce cross-reactivity between closely related microRNAs and indeed the miRCURY platform 
(Exiqon) which employs LNA-enhanced PCR primers showed absolute specificity for members of the 
miR-302 and let-7 families in the microRNA quality control (mirQC) study[43]. The incorporation of 
modified nucleotides into primers to enhance binding affinity and use of the microRNA-specific RT 
oligonucleotides discussed above are the two main approaches adopted to improve the specificity of 
RT-qPCR. Particularly for a diagnostic PCR assay, a ‘hot start’ technique should be adopted to 
prevent extension of primers annealed to non-specific templates or to each other (forming primer 
dimers) at low temperatures during assay set-up. 
Unfortunately the hot start protective effect will not prevent subsequent amplification of any primer 
dimers that do form in the early stages of the PCR. Although not currently adapted for detection of 
microRNAs, a novel method to prevent formation of primer dimers and enable amplification of the 
target even in their presence has been reported by Satterfield [44]. In this approach a capture probe 
providing target specificity is linked to a short primer with a low Tm that does not amplify unless the 
capture sequence binds first. These ‘cooperative primers’ amplify template whilst blocking 
propagation of primer dimers [45]. 
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PCR Efficiency 
The accuracy of quantification using RT-qPCR is highly dependent upon constant and high PCR 
efficiency.  RT-qPCR assay efficiency is usually calculated by performing a template dilution series 
and plotting the CT values against the log template amount, and determining the slope of the 
resulting standard curve. However, this method relies heavily upon the assumption that for all 
samples the PCR efficiency of each amplicon is constant and the software used has properly handled 
the baseline fluorescence call [46]. As an alternative, an algorithm called ‘LinRegPCR’ was developed 
to determine PCR efficiency values per sample by fitting a regression line to a subset of data points 
in the log-linear phase (LinReg -version 11.0, download: http://LinRegPCR.HFRC.nl) [47]. If efficiency 
values are low there may be PCR inhibitors in the samples, the primer-probe design may not be 
optimal or inaccurate pipetting may be occurring.  
Normalisation:  endogenous, spike-in or external standard?  
Despite optimisation of the steps discussed above some technical variability will remain between 
samples due to slight differences in starting material, sample processing, RNA extraction, reverse 
transcription and PCR amplification. Delineation of a normalisation strategy to ensure accurate 
quantification for each clinical sample is perhaps the most challenging issue for use of microRNA RT-
PCR in molecular diagnosis [6]. An internal endogenous small RNA with invariant expression would 
constitute the optimum control, particularly for research applications, but identification of a 
universal candidate is unlikely. Considerable effort to identify stable reference microRNAs or other 
small RNAs in various cells, tissues and disease states has had limited success in solid tissues 
[48][49], however definitive reference microRNA(s) for biofluids have yet to be demonstrated.  The 
most appropriate endogenous controls need to be determined empirically for a specific setting as 
recommended in the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines [50] [51].  The consensus in the field is that in addition to a panel of 
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endogenous controls, a spike in exogenous control microRNA such as Caenorhabditis elegans miR-39 
or Arabidopsis thaliana should be used to provide data on recovery and amplification efficiency 
between RNA preps [7][19][16].  
However, due to the difficulties outlined above normalisation to an internal control is unlikely to be 
practical in a clinical diagnostic setting. To enable absolute quantification a dilution series of known 
amounts of synthetic microRNA oligonucleotide (perhaps calibrated by digital PCR as described 
below) can be used to generate cDNA and used as a standard curve for quantitation of the cognate 
endogenous microRNA [9]. Typically clinical assays are performed on a fixed volume of serum or 
plasma, therefore the assay could report the number of microRNA copies per ml.  
Choice of microRNA RT-qPCR assay 
The choice of qPCR strategy, polyA tailing of the microRNA followed by RT using an oligo(dT) primer 
or direct RT methodologies utilising microRNA-specific RT primer(s), will depend upon application 
but comparative studies can provide a guide. The difference in copy number estimations for some 
microRNAs reported for TaqMan microRNA or miRCURY LNA Universal  RT microRNA PCR (Exiqon) 
assays highlights the significant impact that choice of RT-qPCR technology can have upon microRNA 
measurements [19]. A comprehensive study by Mestdagh et al [43] compared 7 different qPCR 
strategies for microRNAs from 5 different vendors (miRCURY (Exiqon),  OpenArray (Life 
Technologies), TaqMan Cards (Life Technologies), TaqMan Cards preAmp (Life Technologies), 
miScript (Qiagen), qScript (Quanta BioSciences) and SmartChip (WaferGen)). They assessed the main 
criteria for an assay; reproducibility, specificity, sensitivity and accuracy with high and low RNA input 
amount. Transforming these metrics into a Z score allowed for direct comparisons between 
platforms; each had specific strengths and weaknesses which should be taken into consideration 
when choosing an assay for your microRNA qPCR molecular diagnostic assay. We have summarised 
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the advantages and disadvantages associated with the alternative choices available at each step in 
development of a microRNA PCR strategy in Table 1. 
Future directions 
PCR is already supporting point of care diagnostics, with results possible in as little as 15-20 minutes 
(for example the alere q (Alere) and cobas Liat PCR System (Roche)). The demonstration that a PCR 
reaction can be completed in less than a minute [52] has provided the proof of principle that assay 
time could be further reduced to provide even more timely information to the physician (pending 
successful resolution of the numerous technical challenges). Given the potential of circulating 
microRNAs as biomarkers [6][8, 16][53][3], this is likely to be one of the first point of care 
applications involving RT-PCR of microRNAs [2]. We have already shown that a panel of microRNAs 
can be amplified from plasma cDNA in less than 10 min using the xxpress thermal cycler (BJS 
Biotechnologies) that employs resistive heating and forced air cooling to enable ramp rates of up to 
10°C/s [54].   
Miniaturisation of qPCR assays can enable molecular diagnostics labs to offset the cost of increased 
throughput and the advent of 384 and 1536 microplates for qPCR assays has made this feasible. 
However, in order to maintain data integrity and accuracy at such low volumes liquid handling 
machinery must be utilised. For example, extremely low volumes can be dispensed accurately by the 
Echo liquid handler (Labcyte Inc) which employs acoustic ejection of 25nl droplets [55]. This system 
eliminates the need for costly disposable tips and was used to prepare the 2µl PCR reactions from 
which the amplification curves shown in figure 2 were generated. In addition to reducing reagent 
costs, the ability to transfer such small volumes can simplify assay design by eliminating dilution 
steps.  Another advantage of reducing assay volumes is that less cDNA is required. Therefore more 
microRNAs can be assayed from each sample, facilitating the use of expanded diagnostic panels, or 
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assays can be performed on fewer starting cells (only 100 cells in the amplification depicted in Figure 
2) an important consideration for detection of microRNAs from circulating tumour cells.  
The development of qPCR and recent increasing role for digital PCR (dPCR) and NGS has been 
reviewed recently in Biomolecular Detection and Quantification [56]. dPCR enables absolute 
quantification of a target nucleic acid and is beginning to replace qPCR for some applications.  The 
target is diluted across a number of partitions (individual PCR reactions) resulting in some without 
any template; the number of target molecules initially present can be determined from the numbers 
of positive and negative reactions. The myriad potential applications of dPCR in molecular 
diagnostics are beyond the scope of this review, but  it offers an alternative highly sensitive 
approach for the quantitative detection of low abundance microRNAs [57][58][59][60] and would 
reduce the need for a reference microRNA for normalisation. Despite the proposed benefits, dPCR is 
not without some caveats. It is more labour intensive than qPCR and as it still relies on PCR is subject 
to some of the same pitfalls. The main application of dPCR in molecular diagnostics in the immediate 
future is likely to be in the calibration of standards for RT-qPCR [61].  
Perhaps the ultimate solution for accurate quantitation of microRNAs will be to combine RT-PCR 
with next generation sequencing (NGS) technology and employ a ‘molecular indexing’ strategy 
analogous to that used by Cellular Research to measure mRNA abundance[62]. Labelling of each 
microRNA cDNA product with a unique sequence tag present in the RT primer would enable biases 
introduced during PCR to be corrected; counting the number of unique index sequences would 
provide a quantitative measure of the number of microRNA molecules present in the sample.  This 
global approach has the advantage of revealing the isomiRs present [10] and discriminating between 
microRNA families with similar sequences.  
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Expert commentary 
It is important that microRNA isomiRs are considered in the design of a PCR assay. These sequence 
variants are ubiquitous and the relative proportions of isomiRs for any given microRNA will vary 
depending upon the sample type [11]. Therefore an isomiR-specific assay, typically involving a 
dedicated stem-loop RT step, may not accurately reflect the total expression of the microRNA 
concerned. Alternatively, assays involving polyadenylation and oligo(dT)-based RT steps potentially 
detect all isomiRs. Depending upon the requirements of the assay, either approach may be suitable. 
Comparative studies are available to assist in the choice of the most appropriate assay [43]. 
Perhaps the most difficult challenge to the use of microRNA PCR assays for molecular diagnosis is 
definition of an effective normalisation strategy. Many technical factors, particularly sample 
handling and RNA extraction, can influence the microRNA expression level reported by an assay. As 
emphasised in the MIQE guidelines for mRNA qPCR assays [50] [51], it is necessary to determine a 
panel of endogenous control small RNA genes that are stably expressed in the samples under 
investigation. These should be combined with appropriate exogenous spike-in controls. 
 
Five-year view 
Nucleic acid extraction is a significant source of bias. Therefore it is likely that methods involving 
direct lysis will become more prominent, supported by the ongoing advances in analyses of single or 
small numbers of cells [63]. Concomitant with this trend is the miniaturisation of PCR assays, which 
both reduces reagent costs and enables more microRNAs to be measured. Acoustic liquid transfer, 
as delivered by the Echo systems (Labcyte Inc), provides the ability to accurately transfer nanolitre 
volumes without tips. Despite the high capital cost, the advantages of assay miniaturisation and 
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reduced cross contamination risk will drive the wider adoption of this technology for microRNA PCR 
assays. 
There is increasing realisation of the importance of isomiRs [12][11], particularly in the biomarker 
field; therefore a greater awareness of which isomiRs are detected by each assay will be required. 
Combination of PCR assays with NGS will provide the advantages of both technologies, namely 
ability to detect informative microRNAs from small samples with sequence information. Similar 
approaches are already being developed commercially for quantification of mRNAs by, for example, 
Cellular Research Inc and Bio Spyder. Cellular research have pioneered the application of ‘molecular 
indexes’ which facilitate absolute quantification from single cells [62], while Bio Spyder employ 
‘detector oligos’ which in the presence of target sequences are amplified and subsequently 
sequenced, avoiding the need for RNA extraction and reverse transcription. PCR offers specificity for 
selected microRNAs of interest, while subsequent sequencing of the amplification products would 
provide sequence level data about isomiR expression. 
 
Key issues 
• There are two main approaches to detecting microRNA: polyadenylation and oligo(dT) and 
microRNA-specific RT primer.  
• Choice of RNA isolation method can influence the detection of microRNAs and should be 
optimised for the specific sample type under investigation. Direct lysis is an appealing 
alternative to simplify assays and reduce bias introduced during RNA extraction.  
• MicroRNAs exist as a series of variants or isomiRs and the choice of RT-PCR strategy will 
determine whether all or only selected isomiRs will be detected. Polyadenylation followed 
by oligo(dT)-directed RT can detect all 3′ isomiRs whilst microRNA specific stem-loop RT 
focuses on one or a subset of isomiRs. 
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• Future techniques will likely combine RT-PCR with sequencing to provide quantitative data 
on all isomiRs present. 
• Design of primers to discriminate between closely related microRNA sequences is 
challenging due to their short length, but can be aided by inclusion of high affinity modified 
nucleotides. 
• Careful primer design and use of hot start techniques to minimise amplification of off-target 
sequences and primer dimers maximises the sensitivity and specificity of microRNA 
detection. New approaches are being developed to reduce propagation of primer dimers.  
• Miniaturisation of RT-PCR assays made possible with advances in liquid handling technology 
reduces reagent costs and facilitates evaluation of more microRNAs from limited samples. 
• Appropriate normalisation is critical to achieve reliable detection of microRNAs and a panel 
of endogenous controls empirically evaluated for the specific situation combined with 
exogenous ‘spike-ins’ is recommended. 
• The availability of rapid thermal cycling devices is reducing the time required to detect 
microRNAs and it is now possible to complete the PCR stage in less than 10 minutes. 
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Table 1. Summary of the advantages and disadvantages associated with the alternative choices 
available at each step in development of a miRNA PCR strategy 
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PHASE OF STRATEGY OPTIONS AVAILABLE 
RNA extraction Phenol/chloroform Column None (RT directly from lysate) 
Advantages Advantages Advantages 
Relatively inexpensive; 
ability to isolate from a 
large volume of fluid 
Fast, simple 
protocol amenable 
to automation 
No loss of miRNA or bias inherent 
with RNA extraction methods; 
ability to analyse small volumes 
(valuable for limited clinical 
samples); speed  
Disadvantages Disadvantages Disadvantages 
Relatively time 
consuming and not 
amenable to 
automation, therefore 
not suitable for large 
numbers of samples; 
Health and safety 
concerns 
Starting volume 
limited; expensive 
QC of RNA not possible; 
Commercial lysis buffer expensive 
(“homemade” buffer an option); 
Not yet widely characterised 
Summary Summary Summary 
Speed *; Sensitivity 
***; Cost **; 
Reproducibility ** 
Speed ***; 
Sensitivity**; Cost 
*; Reproducibility 
*** 
Speed ***; Sensitivity **; Cost 
***; Reproducibility ** 
RT Strategy Poly-A miRNA-Specific stem loop miRQPCR (linker) 
Advantages Advantages Advantages 
Single universal RT 
suitable for 
subsequent detecton 
of all miRNAs of 
interest and also 
amenable to analysis 
of mRNA. Detects all 
microRNA isomiRs 
High sensitivity and 
specificity; can be 
multiplexed; 
isomiR specificity 
Universal ligation and RT steps for 
subsequent detecton of all 
miRNAs of interest 
Disadvantages Disadvantages Disadvantages 
Sensitivity limited by 
background; requires 
additional 
polyadenylation setp; 
does not discriminate 
between isomiRs 
Specific RT 
reaction required 
for each miRNA; 
expensive 
Involves an extra ligation step  
Summary Summary Summary 
Speed **; Sensitivity 
**; Cost ***; 
Reproducibility ** 
Speed **; 
Sensitivity***; 
Cost *; 
Reproducibility *** 
Speed **; Sensitivity***; Cost 
***; Reproducibility ** 
Detection Chemistry Double-stranded 
DNA intercalating 
molecules, e.g. 
SYBR Green or 
Oligonucleotide 
probe-based 
fluorescent 
detection e.g. 
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EvaGreen Taqman, 
Scorpion or 
PNA 
Advantages Advantages 
Low cost, melt curve 
available to check 
specificity 
Increased 
specificity and 
sensitivity; primer 
dimers less critical 
provided PCR 
efficiency 
maintained; 
potential to 
perform multiplex 
reactions 
Disadvantages Disadvantages 
Primer dimers 
contribute to increases 
in fluorescence; 
typically requires user 
design, Dye inhibition 
of PCR and effect on 
melt curve analysis; 
preferential binding to 
GC rich sequences. 
Expensive; 
maximum rate of 
extension reduced  
Summary Summary   
Speed ***; Sensitivity 
**; Cost ***; 
Reproducibility ** 
Speed **; 
Sensitivity***; 
Cost *; 
Reproducibility *** 
  
Standardisation/ 
Normalisation Standards 
Internal 
Reference 
  
Advantages Advantages 
Common practice in 
molecular diagnostics, 
providing an absolute 
value; reduces need to 
find a “housekeeping” 
miRNA 
Less laborious than 
generating 
standards; controls 
for some sample-
specific variables 
Disadvantages Disadvantages 
Involves additional 
reactions; 
Concentrations of 
standars must be 
determined accurately 
(eg by digital PCR) 
More appropriate 
for research 
applications than  
clinical diagnostics; 
difficult to 
establish reliable 
“housekeeping” 
miRNA particularly 
in biofluids 
Summary Summary   
Speed *; Sensitivity 
NA; Cost *; 
Reproducibility *** 
Speed **; 
Sensitivity NA; Cost 
**; Reproducibility 
**   
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Figure 1. Overview of potential microRNA RT-qPCR workflows. The key steps indicated in  blue 
boxes are  common to all protocols, with the exception of RNA extraction which can be 
circumvented by performing reverse transcription directly upon lysed sample.  Sequencing of PCR 
products provides an alternative to qPCR to provide isomiR information in addition to 
quantification of the amplicons. The alternative strategies available at the ‘Reverse transcription’ 
and ‘Quantification’ steps are provided in red, purple and green boxes and are detailed in the text.
Tissue
Reverse transcription
PCR
Quantification
Normalisation
Polyadenylation
Probes SYBR
OligodTStem-loop
Direct 
lysis
Sequencing
Digital 
quantification 
of all isomiRs
Relative quantification of 
single isomiRs 
or total miRNA
Linker ligation
RNA extraction & QC
Linker
 
 
miR-22
miR-34a
Figure 2 . Low volume RT-PCR directly from cell lysates. 100 endothelial colony forming cells (ECFCs) [25] were 
lysed with 10µl in-house detergent buffer [24]. Reverse transcription and quantitative real time PCR was 
performed with TaqMan assays for miR-22 and miR-34a in a 2µl reaction volume using a Roche LightCycler 480.
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Figure 3. Comparison of polyadenylation and oligodT with 
microRNA-specific stem-loop RT strategies. The miR-133a-3p TaqMan
assay preferentially reverse transcribes the mature sequence (bold) 
while all 3′ isomiRs are detected with the oligo-dT based RT 
oligonucleotide. Both assays employ a miRNA-specific forward primer 
(often with modified nucleotides (*)) and a reverse primer 
complementary to sequences introduced by the RT oligo to amplify 
the target microRNA. RPM: reads per million
polyA RT-PCR
UUUGGUCCCCUUCAACCAGC................ 132
UUUGGUCCCCUUCAACCAGCU............... 76
UUGGUCCCCUUCAACCAGCUG.............. 51
UUUGGUCCCCUUCAACCAG................. 47
UGGUCCCCUUCAACCAGCUGU............. 45
UUUGGUCCCCUUCAACCAGCUG.............. 39
UUUGGUCCCCUUCAACCAGCUGU............. 32
UUGGUCCCCUUCAACCAGCUGUA............ 28
UUGGUCCCCUUCAACCAGC................ 24
UUGGUCCCCUUCAACCAGCUGU............. 23
UUUGGUCCCCUUCAACCAGCAAAAAAAAAAAAAAAA
UUUGGUCCCCUUCAACCAGCUAAAAAAAAAAAAAAA
UUGGUCCCCUUCAACCAGCUGAAAAAAAAAAAAAA
UUUGGUCCCCUUCAACCAGAAAAAAAAAAAAAAAAA
UGGUCCCCUUCAACCAGCUGUAAAAAAAAAAAAA
UUUGGUCCCCUUCAACCAGCUGAAAAAAAAAAAAAA
UUUGGUCCCCUUCAACCAGCUGUAAAAAAAAAAAAA
UUGGUCCCCUUCAACCAGCUGUAAAAAAAAAAAAA
UUGGUCCCCUUCAACCAGCAAAAAAAAAAAAAAAA
UUGGUCCCCUUCAACCAGCUGUAAAAAAAAAAAAA
NVTTTTTTTTTTTTTTTT
UUUGGUCCCCUUCAACCAGCUG
Stem-loop
RPM
AAACCAGGGGAAGTTGG
*  *  
TTTTTTTTTTTTTTTTAAACCAGGGGAAGTTGGTC
cDNA
*  *  
PCR primers
GACAT
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